Buy Rating for Nurix Therapeutics: Strong Cash Position and Upcoming Catalysts Justify $36 Price Target Despite Wider Net Loss
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a ...
Nurix Therapeutics price target raised to $17 from $16 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Nurix Therapeutics (NRIX) to $17 from $16 and keeps an Equal Weight ...